María Jesús Rubio-Pérez

8PUBLICATIONS
56CO-AUTHORS
Predictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 12, 2026
Immunotherapy in Endometrial Cancer: Molecular Classification, Clinical Evidence, and Therapeutic Implications: A Narrative Review.

|May 20, 2025
Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study.

Maria Quindós-Varela, Diego Soto de Prado-Otero, Alejandro Gallego

|Nov 26, 2024
First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial.

Christian Marth, Richard G Moore, Mariusz Bidziński

|Sep 18, 2024
Atezolizumab Combined With Platinum and Maintenance Niraparib for Recurrent Ovarian Cancer With a Platinum-Free Interval >6 Months: ENGOT-OV41/GEICO 69-O/ANITA Phase III Trial.

Antonio González-Martín, María Jesús Rubio, Florian Heitz

|Aug 01, 2023
Analysis of Tumor Microenvironment Changes after Neoadjuvant Chemotherapy with or without Bevacizumab in Advanced Ovarian Cancer (GEICO-89T/MINOVA Study).

Beatriz Tavira, Teresa Iscar, Luis Manso

|Apr 28, 2023
Controversies in the treatment of advanced ovarian cancer in the PARP inhibitors era: a Delphi consensus.

Andrés Redondo, Pilar Barretina, Alejandro Pérez-Fidalgo

Pageof 2

Frequent Collaborators

4 joint publications

Pilar Barretina

3 joint publications

Antonio González-Martín

3 joint publications

José Alejandro Pérez-Fidalgo

2 joint publications

Luisa Sánchez-Lorenzo